Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and commercialization of immunology based therapies for patients in need.
Zenas is rapidly advancing a deep pipeline of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases.
Vision & Values
At Zenas, we strive to be a truly innovative company. Our vision is to be a global leader in bringing innovative immunology based medicines to patients around the world. We are guided by our core value system: TRUE Innovation.
We will communicate openly and honestly, even when having difficult conversations.
We are unified in the high value we place on both our internal relationships with each other and our external relationships with our partners and collaborators.
We are all fully engaged with a sense of urgency to realize our vision.
We aspire to the highest levels of teamwork and results-oriented execution, and we will measure and communicate our results.
We will be creative, open to change, adaptable to new ways of thinking and operating with a “why not?” attitude.
Founder, CEO & Chairman
Mr. Moulder, Founder of Zenas BioPharma, is our Chief Executive Officer and Chairman. Prior to Zenas, he co-founded and served as CEO and Director at TESARO, until its acquisition by GlaxoSmithKline in January 2019. Before founding TESARO, Mr. Moulder was President and CEO of Abraxis BioScience. He also previously served as Vice Chairman of Eisai Corporation of North America after Eisai’s acquisition of MGI PHARMA, where he was President and CEO. This followed him serving as a member of the founding management team of a venture-stage biotech company. Mr. Moulder began his career as a clinical pharmacist followed by a 17-year career at predecessor companies of Sanofi, beginning with Marion Laboratories.
Mr. Moulder is Managing Member of Tellus BioVentures and serves as a Board of Director for several Tellus portfolio companies. He also serves as a Director for Zai Lab (Nasdaq: ZLAB). Mr. Moulder is a Temple University Trustee; Chair of Temple University Japan; and a Council Member for both the University of Chicago Booth School of Business and the Polsky Center for Entrepreneurship and Innovation. Mr. Moulder received a Pharmacy degree from Temple University and an MBA from The University of Chicago Booth School of Business.
President & Chief Operating Officer
Mr. Farmer is the President and Chief Operating Officer of Zenas BioPharma. He is an accomplished biopharma executive with over 25 years of transactional and operational experience working with emerging biotechnology companies at all stages of development, from discovery through commercialization. Prior to joining Zenas, he served as Chief Operating Officer at Xilio Therapeutics, an immuno-oncology company, where he led the general and administrative, business development, and business operations functions. Prior to Xilio he was the General Counsel and Corporate Secretary at TESARO, where he led the global legal, compliance and government affairs functions and was a key member of the leadership team through its acquisition by GlaxoSmithKline in 2019. He previously served as Chief Corporate Counsel at Cubist Pharmaceuticals through its acquisition by Merck in 2015 and as General Counsel at two publicly traded companies, including AMAG Pharmaceuticals, where he was also the Chief Administrative Officer. He began his career as a corporate attorney at Testa Hurwitz & Thibeault.
Throughout his career, Mr. Farmer has been involved in numerous large and complex financing, business development, and M&A transactions, together approaching $20 billion in aggregate value. He received his J.D. from Boston College Law School and his B.A. in economics from Boston University.
Chief Business Officer & Chief Financial Officer
Ms. Fox is the Chief Business Officer and Chief Financial Officer at Zenas BioPharma. She is an experienced finance and corporate development executive with more than 25 years of experience in corporate finance and healthcare investment banking, advising numerous private and public companies with respect to strategy, financings and mergers and acquisitions. Prior to joining Zenas, Ms. Fox served as Chief Financial Officer at Nuvation Bio, a publicly traded biotechnology company, where she was part of the executive leadership team and had an integral role in establishing the strategic and financial direction of the company. She previously served as a Managing Director and Co-Head of North America Healthcare Corporate and Investment Banking Group at CitiGroup. Prior to CitiGroup, Ms. Fox held senior positions in investment banking at Deutsche Bank, Bear Stearns, Bank of America and Prudential Securities. She holds B.S. degrees in finance and marketing from Manhattan College.
Tanya Fischer, M.D., Ph.D.
Head of R&D and Chief Medical Officer
Dr. Tanya Fischer is the Head of Research and Development and Chief Medical Officer at Zenas BioPharma. Dr. Fischer is a physician-scientist with 20 years of experience in academia and at pharmaceutical/ biotechnology companies leading early and late-stage research and development programs across multiple therapeutic areas including Neurology and Rare Diseases.
Prior to joining Zenas, she served as the Chief Development Officer and Head of Translational Medicine at Biohaven, a pharmaceutical company focused on neurological conditions. Prior to Biohaven, Dr. Fischer also held leadership roles at Alnylam and Sanofi. While at Alnylam, she was responsible for expanding the CNS pipeline and initiating a Phase 1 trial. At Sanofi, she was responsible for leading the flagship global project teams in clinical development (Phase 1 through Phase 3) for a rare genetic form of Parkinson’s Disease and related rare neurodegenerative diseases (such as Gaucher disease (type 3) and GM2 gangliosidosis, as well as genetic forms of ophthalmology.
Dr. Fischer is a neurologist, with clinical subspecialties in demyelinating diseases and chronic neuropathic pain. Dr. Fischer completed her Neurology residency at Yale New Haven Hospital. As an Associate Professor at Yale University in Neurology, her VA-supported academic research focused on genetic and acquired forms of pain (ion channels (especially in Nav 1.7) and diabetic neuropathy) with a variety of peer-reviewed paper. She also was awarded the prestigious Presidential Early Career Award for Scientists and Engineers (PECASE) Award in 2011. The PECASE Awards are intended to recognize some of the finest scientists and engineers who, while early in their research careers, show exceptional potential for leadership at the frontiers of scientific knowledge during the twenty-first century.
Gan Wei, Ph.D.
Senior Vice President, Global Technical Operations
Dr. Wei is Senior Vice President, Global Technical Operations at Zenas BioPharma. Prior to joining Zenas, he served as Vice President, Interim Head of Technical Operations at Voyager Therapeutics. Previously, Dr. Wei was the Senior Director of Biologics Process Development at Momenta Pharmaceuticals, followed by Executive Director of Biologics Drug Substance and Analytical Sciences at TESARO. Dr. Wei has over 20 years of experience in the biopharmaceutical industry spanning biologics process development and cGMP manufacturing support, including commercialization to life cycle management. He has led CMC for multiple programs from IND-enabling through successful registration. Dr. Wei received a Ph.D. and M.S. in Chemical and Biochemical Engineering from the University of Maryland, Baltimore County, and an M.S. and B.S. in Biochemical Engineering from East China University of Science and Technology.
Senior Vice President, Human Resources
Ms. Chevalier is the Senior Vice President, Human Resources at Zenas BioPharma. Ms. Chevalier leads the Human Resource Operations function for the U.S. and has more than 15 years of human resources experience within the pharmaceutical and biotechnology industry. Prior to joining Zenas, she served as Vice President, Human Resources at Deciphera Pharmaceuticals. Prior to Deciphera, Ms. Chevalier was Senior Director, Total Rewards & Human Resource Operations at TESARO where she was responsible for developing and implementing scalable policies and programs to attract and retain talent in a high growth, global organization. Ms. Chevalier also held several roles of increasing responsibility at Cubist Pharmaceuticals in her 12 year tenure during which she gained experience across all aspects of Human Resources, supporting the organization through commercialization, global expansion and multiple acquisitions. Ms. Chevalier received a B.A. in Economics from Boston College.